Frontier Biotechnologies Inc. (SHA:688221)

China flag China · Delayed Price · Currency is CNY
19.05
-0.86 (-4.32%)
At close: Mar 19, 2026
Market Cap7.14B +87.9%
Revenue (ttm)143.67M +11.0%
Net Income-261.72M
EPS-0.70
Shares Out374.58M
PE Ration/a
Forward PE792.86
Dividendn/a
Ex-Dividend Daten/a
Volume10,259,600
Average Volume13,801,017
Open19.80
Previous Close19.91
Day's Range18.93 - 20.08
52-Week Range7.16 - 29.98
Beta1.08
RSI44.97
Earnings DateMar 31, 2026

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and me... [Read more]

Sector Healthcare
Founded 2002
Employees 524
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688221
Full Company Profile

Financial Performance

In 2025, Frontier Biotechnologies's revenue was 143.67 million, an increase of 10.96% compared to the previous year's 129.47 million. Losses were -261.72 million, 30.0% more than in 2024.

Financial Statements